CELCUITY LLC
NASDAQ: CELC (Celcuity Inc.)
Kemas kini terakhir: 6 jam lalu104.51
-0.36 (-0.34%)
| Penutupan Terdahulu | 104.87 |
| Buka | 105.05 |
| Jumlah Dagangan | 407,742 |
| Purata Dagangan (3B) | 837,549 |
| Modal Pasaran | 4,835,809,280 |
| Harga / Buku (P/B) | 41.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -3.05 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 113.89% |
| Nisbah Semasa (MRQ) | 6.61 |
| Aliran Tunai Operasi (OCF TTM) | -102.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.83 M |
| Pulangan Atas Aset (ROA TTM) | -39.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Celcuity Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.40 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.21% |
| % Dimiliki oleh Institusi | 81.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sio Capital Management, Llc | 30 Sep 2025 | 786,526 |
| Apis Capital Advisors, Llc | 30 Sep 2025 | 776,000 |
| Deerfield Management Company, L.P. | 30 Sep 2025 | 733,530 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 134.00 (Jefferies, 28.22%) | Beli |
| Median | 118.00 (12.91%) | |
| Rendah | 94.00 (HC Wainwright & Co., -10.06%) | Pegang |
| Purata | 116.00 (10.99%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 96.65 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 12 Dec 2025 | 126.00 (20.56%) | Beli | 105.25 |
| Jefferies | 02 Dec 2025 | 134.00 (28.22%) | Beli | 97.50 |
| Wolfe Research | 18 Nov 2025 | 110.00 (5.25%) | Beli | 91.60 |
| HC Wainwright & Co. | 17 Nov 2025 | 94.00 (-10.06%) | Pegang | 92.23 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ROMP CHARLES R | 104.23 | - | 215 | 22,409 |
| Jumlah Keseluruhan Kuantiti Bersih | 215 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 22,409 | |||
| Purata Pembelian Keseluruhan ($) | 104.23 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ROMP CHARLES R | Pengarah | 11 Feb 2026 | Diperolehi (+) | 215 | 104.23 | 22,409 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |